Quantcast

Latest Nicholas J. Vogelzang Stories

2014-10-02 08:28:50

Results, Published in Clinical Genitourinary Cancer, Offer Key Insights and Potential New Treatment Strategies for Patient Population with Limited Drug Options IRVING, Texas, Oct. 2, 2014 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of precision medicine, announced the publication of a study in which Caris Molecular Intelligence(TM), the company's comprehensive tumor profiling service, was used to identify actionable biomarkers in...

2014-09-29 08:29:46

Final data after 49-month follow-up analysis in chemotherapy-naïve men with metastatic castration-resistant prostate cancer presented at European Society for Medical Oncology (ESMO) 2014 Congress TORONTO, Sept. 29, 2014 /CNW/ - A final analysis of the Phase 3 COU-AA-302 trial presented at the European Society for Medical Oncology (ESMO) conference in Madrid, Spain showed that ZYTIGA(®) (abiraterone acetate) plus prednisone significantly prolonged overall survival (OS), compared to...

2014-09-28 08:21:14

Final analysis of Phase 3 COU-AA-302 study presented at the European Society for Medical Oncology (ESMO) 2014 Congress HORSHAM, Pa., Sept. 28, 2014 /PRNewswire/ -- A final analysis of the Phase 3 COU-AA-302 trial presented today at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain showed that ZYTIGA(®) (abiraterone acetate) plus prednisone significantly prolonged overall survival (OS), compared to an active control of placebo plus prednisone, in men...

2014-07-16 23:08:14

Researchers say pemetrexed (Alimta), the top chemotherapy drug for mesothelioma, may carry a risk of acute kidney injury, even in patients whose baseline kidney function falls within recommended limits. Raleigh, NC (PRWEB) July 16, 2014 Italian scientists say patients on the popular mesothelioma drug pemetrexed may need to take certain precautions to avoid damaging their kidneys. An article on the new research has just been published on the Surviving Mesothelioma website. Click here to...

2014-06-26 08:26:57

LONDON, June 26, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: KOL Insight: Prostate Cancer: Competition intensifies in race to the tophttp://www.reportbuyer.com/pharma_healthcare/diseases/kol_insight_prostate_cancer_competition_intensifies_race_top.html IntroductionThe Prostate Cancer market has seen a number of progressive changes in recent years. The launches of Johnson & Johnson's Zytiga (abiraterone acetate) and Medivation/Astellas's Xtandi...

2014-06-02 08:30:44

Phase 2 study data presented at the 50th annual meeting of the American Society of Clinical Oncology HORSHAM, Pa., June 2, 2014 /PRNewswire/ -- Abiraterone acetate (ZYTIGA(®)) plus prednisone demonstrated statistically significant reductions in PSA levels at six months, the primary endpoint of the IMAAGEN trial, which evaluates the investigational use of abiraterone acetate plus prednisone (5 mg once daily) in patients with non-metastatic castration-resistant prostate cancer...

2014-05-29 08:28:58

Appointees join Caris' distinguished clinical and scientific team to accelerate the development and commercialization of innovative precision medicine technologies IRVING, Texas, May 29, 2014 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of precision medicine, announced today that it has assembled leading scientists and clinical experts to join its newly created Scientific Advisory Board (SAB). This team will assist the...

2014-05-20 16:26:25

Two Studies Presented at 2014 AUA Annual Meeting SAN DIEGO, May 20, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced the presentation of data showing that its Decipher® Prostate Cancer Classifier, a genomic test capable of predicting metastatic prostate cancer, was able to identify patients that may be spared of radiation therapy after prostate surgery who would have been otherwise classified as high risk based on current clinical practice guidelines. In a separate study,...

2014-05-05 20:23:52

LONDON, May 5, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Renal Cell Carcinoma Global Clinical Trials Review, H1, 2014http://www.reportbuyer.com/pharma_healthcare/research_rd/clinical_trials/renal_cell_carcinoma_global_clinical_trials_review.htmlRenal Cell Carcinoma Global Clinical Trials Review, H1, 2014SummaryGlobalData's clinical trial report, "Renal Cell Carcinoma Global Clinical Trials Review, H1, 2014" provides data on the Renal Cell Carcinoma...

2014-04-23 08:31:00

Third Phase 3 Trial of Custirsen to Receive FDA Fast Track Designation BOTHELL, Wash. and VANCOUVER, British Columbia, April 23, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of custirsen when administered in combination with cabazitaxel/prednisone for the treatment of men with metastatic castrate-resistant prostate cancer (CRPC) following...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.